Introduction {#sec1}
============

Eritrea has a projected total population of 3,905,066 in 2018 including an estimated 117,152 surviving infants. Children less than 5 years of age are estimated to make up 15% of the total population. The country is divided into six administrative regions known as Zobas: Gash Barka, Anseba, Debub, Maekel, Debubawi Keih Bahri and Semanawi Keih Bahri Zobas (Zones), which in turn are divided into 58 subzobas (sub-zones) \[[@cit0001]\]. The 2018 report of the UN Inter-Agency Group for Child Mortality Estimation indicates that, in Eritrea, under-five mortality rate was reduced from 151 per 1,000 live births in 1990 to 43 per 1,000 live births in 2017. Infant mortality rate was also reduced from 93 per 1,000 live births in 1990 to 32 per 1,000 live births in 2017 \[[@cit0002]\]. The second national Health Sector Strategic Development Plan of Eritrea for 2017 - 2021 (HSSDP-II) further aims to reduce under-five and infant mortality rates to 32 and 25 per 1,000 live births respectively \[[@cit0003]\].

The Expanded Program on Immunisation (EPI) has been operational in Eritrea since 1980. Currently, the EPI program is housed as a unit within the Department of Public Health and is responsible to the director of family and community health division. EPI service delivery is integrated with other maternal and child health services and it is delivered as a package in all health facilities. By 2017, the ministry of health was providing healthcare service through 349 health facilities, in three-tier structure - namely primary care level, secondary care level and tertiary care level. A total of 295 (85%) health facilities provide routine immunization services 6 days per week in the country. In addition, immunization service is provided at 450 outreach sites across the country \[[@cit0001]\]. The HSSDP-II prioritizes, among others, the delivery of accessible and equitable immunization service for children below 5 years of age using the reaching every district approach \[[@cit0003]\]. As of 2019, the national EPI schedule includes antigens against 11 vaccine preventable diseases. These include a dose of BCG vaccine provided at birth, three doses of pentavalent vaccine (DPT/HiB/hepatitis B) and pneumococcal vaccine (PCV13) at 6, 10 and 14 weeks of age, four doses of oral polio vaccine (at birth, at 6, 10 and 14 weeks), Injectable Polio Vaccine (IPV) at 14 weeks of age, 2 doses of measles-rubella vaccine at 9 months and 18 months of age, and 2 doses of rotavirus vaccines at 6 and 10 weeks of life. Every woman of childbearing age (15 - 45 years) is expected to receive 5 doses of tetanus toxoid and diphtheria (Td) vaccine as per the WHO recommendations \[[@cit0004]\].

In 2011, the WHO African Region adopted a regional measles elimination goal for 2020, comprised of the following targets: 1) ≥ 95% coverage with the first dose of measles-containing vaccine (MCV1) at national and district levels; 2) ≥ 95% coverage in all districts during measles supplemental immunization activities (SIAs); 3) confirmed measles incidence \< 1 per million population in all countries; 4) attaining high quality measles surveillance - to investigate ≥ 2 cases of non-measles febrile rash illness (NMFRI) per 100,000 population annually, and to obtain a blood specimen from ≥ 1 suspected measles case in ≥ 80% of districts annually \[[@cit0005]\]. The regional measles elimination goal is reflected as one of the objectives of the regional immunisation strategic plan 2014 - 2020 \[[@cit0006]\]. In line with the Regional goals, the Eritrean national comprehensive Multi-year plan for immunization (2017 - 2021) aims to achieve \> 95% vaccination coverage with the first dose of measles-rubella vaccine (MR1) and 90% with the second dose of MR by 2021 \[[@cit0001]\]. This manuscript aims to describe the performance of Eritrea in the implementation of measles elimination strategies, the epidemiology of measles in the country and the overall progress towards measles elimination as at end of 2018.

Methods {#sec2}
=======

**Routine immunization:** the antigens provided to eligible persons as part of the routine immunization service are recorded and reported by health facilities to the sub-zobas, and the zobas, and onward to the National Immunization Programme. Sub-national and national coverage is calculated against the respective denominator targets and the national level coverage is reported annually to WHO and UNICEF. WHO and UNICEF use coverage data from administrative reporting and from surveys to generate coverage estimates for each antigen provided through the routine immunization services \[[@cit0007]\]. We analyzed the administrative measles vaccination service data, coverage information from surveys and the annual WHO-UNICEF measles vaccination coverage estimates for Eritrea for the years 1993 - 2017.

**Supplemental immunization**: Eritrea has been conducting preventive measles supplemental immunization activities (SIAs) periodically since 2003. At the end of each SIAs, technical reports are compiled, and often coverage surveys are done to corroborate administrative coverage levels. We reviewed the various technical reports and coverage survey results following the measles SIAs conducted in Eritrea between 2003 and 2018 \[[@cit0008]\].

**Measles surveillance and disease incidence:** Eritrea established measles case-based surveillance, with the support of a national serological laboratory for the confirmation of measles cases starting in 2005. Measles surveillance protocols as well as the methods and tools used by the measles serological laboratory network are standardized across the WHO African Region \[[@cit0009]\]. We analyzed the surveillance database for the years 2005 to 2018. We reviewed the epidemiological pattern of measles cases confirmed by laboratory testing, epidemiological linkage or clinical criteria. Measles IgM negative specimens are tested for rubella IgM as part of the standard protocol. We reviewed the number of lab confirmed rubella cases reported in the same period.

Measles surveillance performance is monitored using standard performance indicators. The two principal performance indicators are: non-measles febrile rash illness rate (target of at least 2 per 100,000 population) and the proportion of districts that have investigated at least one suspected case of measles with blood specimen per year (target at least 80% of districts per year). The incidence of confirmed measles is calculated as a rate per million, by dividing the total number of confirmed measles cases (confirmed by laboratory, epidemiological linkage and clinical criteria) by the total population \[[@cit0009]\]. In addition to the analysis of data from the case-based measles surveillance database, we reviewed the official number of measles cases reported by the country annually to WHO and UNICEF through the Joint Reporting Form (JRF) \[[@cit0010]\].

Results {#sec3}
=======

Routine immunization: national coverage with the first and third doses of Diphtheria-Pertussis-Tetanus containing vaccine (DPT1 and DPT3) sharply increased from 49% and 32% respectively in 1993 to 97% and 93% in 1999 according to the WHO UNICEF coverage estimates. During the same period, the first dose of measles vaccine (MCV1) coverage improved from 34% to 88%. Coverage for all antigens dropped by about 10 percentage points in 2000 but recovered by 2002. From 2003 until 2017, vaccination coverage with the primary antigens has been maintained at above 90% ([Table 1](#t0001){ref-type="table"}).

###### 

DPT1, DPT3 and measles first and second dose vaccination coverage according to the WHO UNICEF coverage estimates, Eritrea, 1993 - 2017

         DPT1   DPT3   MCV1   MCV2
  ------ ------ ------ ------ ------
  1993   49%    32%    34%    
  1994   61%    49%    51%    
  1995   68%    58%    58%    
  1996   75%    66%    66%    
  1997   83%    75%    73%    
  1998   90%    86%    79%    
  1999   97%    93%    88%    
  2000   88%    81%    76%    
  2001   91%    86%    84%    
  2002   94%    90%    83%    
  2003   97%    93%    92%    
  2004   99%    98%    96%    
  2005   99%    96%    95%    
  2006   97%    94%    95%    
  2007   98%    95%    96%    
  2008   98%    95%    96%    
  2009   98%    95%    97%    
  2010   98%    95%    97%    
  2011   97%    94%    98%    
  2012   97%    94%    98%    
  2013   97%    94%    94%    
  2014   97%    94%    90%    
  2015   98%    95%    97%    88%
  2016   97%    95%    99%    88%
  2017   97%    95%    99%    88%

Eritrea introduced the second dose of measles vaccine (MCV2) in the routine immunization schedule in July 2012, providing it to children starting at 18 months of age. However, the country started reporting MCV2 coverage to the WHO and UNICEF in 2015. The WHO-UNICEF estimates of MCV2 coverage for 2015 - 2017 have been consistently 88%, with the drop-out rate between the first and second doses of measles vaccine staying at 9 - 11% ([Table 1](#t0001){ref-type="table"}, [Figure 1](#t0001){ref-type="table"}). Eritrea introduced rubella vaccine into the routine immunization schedule in December 2018, following a nationwide measles -rubella catch-up SIAs.

![Officially reported measles cases, and WHO UNICEF coverage estimates. Eritrea. 1993 - 2017.](PAMJ-SUPP-35-1-07-g001){#f0001}

The Demographic Health Survey (DHS) done in Eritrea in 2002 indicated BCG coverage of 91.4%, DPT3 coverage of 82.8% and MCV1 coverage of 84.2% \[[@cit0011]\]. The National EPI coverage survey done in 2017 indicated that 98.9% had received BCG, while 97.3% received the third dose of pentavalent vaccine and 96.8% were vaccinated with the first dose of measles vaccine. Coverage with the second dose of measles vaccine (MCV2) was 86.7% among 24 - 35 months old children. According to the 2017 survey, MCV1 coverage by province ranged from 92.1% in Gash Barka to 99.2% in Maekel and MCV2 coverage ranged between 66.5% in Debubawi Keih Bahri and 92.7% in Maekel \[[@cit0012]\].

**SIAs:** Eritrea conducted the first preventive SIAs against measles in 2003, targeting children from 9 months to 14 years of age and reaching a total of 1,047,862 children (82% of the target). In subsequent years, the country conducted measles follow-up SIAs every 3 years and a wide age range measles-rubella (MR) catch-up SIAs in 2018. Administrative coverage at national level was less than 85% in all SIAs except in 2006. However, coverage surveys conducted after the 2012 and 2018 SIAs both indicated coverage of more than 95% at national level ([Table 2](#t0002){ref-type="table"}) \[[@cit0008], [@cit0013]\]. During the MR catch-up SIAs of 2018, the administrative coverage ranged from 73% in Anseba to 95% in Gash Barka ([Table 3](#t0003){ref-type="table"}). Post-campaign survey results showed \> 95% coverage in all Zobas. Only 5.4% children aged 9 - 59 months of age had no prior measles vaccination prior to the MR SIAs in 2018, according to the survey report.

###### 

Measles supplemental immunization activities (SIAs) coverage in Eritrea, 2003 - 2018

  Year   Age group of children targeted   Number of children vaccinated   Administrative coverage at national level (% of target)   \% districts with administrative coverage ≥ 95%   Coverage survey result
  ------ -------------------------------- ------------------------------- --------------------------------------------------------- ------------------------------------------------- ------------------------
  2003   9 months - 14 years              1,047,862                       82%                                                                                                         Not Done
  2006   6 - 59 months                    387,479                         95%                                                                                                         Not Done
  2009   9 - 59 months                    285,285                         82%                                                                                                         Not Done
  2012   6 - 47 months                    277,928                         75%                                                       16.0%                                             95.6%
  2015   9 - 59 months                    350,765                         80.1%                                                     36.2%                                             Not Done
  2018   9 months - 14 years              1,276,364                       84%                                                       0.0%                                              97.8%

###### 

Measles-rubella supplemental immunization activities (SIAs) administrative and survey coverage at Zoba level, Eritrea, 2018

  Zoba                  Target Population   Vaccinated children   Administrative coverage   Survey coverage
  --------------------- ------------------- --------------------- ------------------------- -----------------
  Maekel                223,020             179,046               80.30%                    99.40%
  Gash Barka            396,981             376,699               94.90%                    97.80%
  Anseba                224,056             163,163               72.80%                    99.60%
  Debub                 368,055             301,595               81.90%                    95.30%
  Semenawi Keih Bahri   191,306             154,047               80.50%                    99.70%
  Debubawi Keih Bahri   36,070              32,200                89.30%                    99.60%
  National              1,439,488           1,206,750             83.80%                    97.80%

**Measles and rubella surveillance performance:** the national level target of 2 non-measles febrile rash illness cases per 100,000 population (NMFRI) has been met since 2010 but the target was missed in 2007 - 2009. However, since 2011, Eritrea has not attained 80% target for districts reporting suspected measles cases with blood specimen ([Table 4](#t0004){ref-type="table"}). The national serological laboratory for the confirmation of suspected measles and rubella cases has recently been accredited since 2010, though with varied performance. Training was done in October 2018. There is no sentinel surveillance system in place to investigate and report congenital rubella syndrome (CRS) cases and no retrospective review has been done to date.

###### 

Measles case-based surveillance performance, Eritrea, 2005 - 2018 (Source: Measles case-based surveillance system)

  Year   Total suspected measles cases   Suspected measles cases that were investigated   Non-measles febrile rash illness (NMFRI) rate -- \[Target: ≥ 2 cases per 100,000 population\]   \% districts investigating suspected cases per year \[Target: ≥ 80% districts\]
  ------ ------------------------------- ------------------------------------------------ ----------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------
  2005   159                             155                                              4.2                                                                                             100%
  2006   125                             125                                              3.9                                                                                             100%
  2007   52                              52                                               1.6                                                                                             100%
  2008   61                              59                                               1.8                                                                                             100%
  2009   45                              45                                               1.2                                                                                             30%
  2010   168                             168                                              4.6                                                                                             83%
  2011   145                             145                                              3.6                                                                                             75%
  2012   243                             243                                              4                                                                                               66%
  2013   139                             139                                              2.3                                                                                             41%
  2014   103                             102                                              2.6                                                                                             36%
  2015   195                             195                                              2.9                                                                                             59%
  2016   334                             334                                              6.8                                                                                             60%
  2017   185                             183                                              3.4                                                                                             36%
  2018   155                             154                                              2.1                                                                                             53%

**Measles and rubella incidence:** between 2005 and 2018, Eritrea reported a total of 2,112 suspected measles cases through the case-based surveillance system, of which 529 were confirmed by laboratory, epidemiological linkage or clinical compatibility. On average, annually, 150 suspected measles cases were reported through the case-based surveillance system. There were 278 laboratory confirmed rubella cases in the same period ([Table 5](#t0005){ref-type="table"}). The incidence of confirmed measles in Eritrea ranged from 0.3 per million in 2008 and 2014 to 24.7 per million population in 2015. The country reported measles incidence levels of less than 1 measles case per million in 2007, 2008, 2009 and 2014. The incidence of confirmed measles was more than 10 per million in 7 out of the 14 years analyzed, including from 2015 - 2018. The peak period of measles occurrence in Eritrea is between January and May in most years. Similar peaks are seen in the occurrence of lab confirmed rubella cases in the first half of the year ([Figure 2](#f0002){ref-type="fig"}).
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###### 

Measles incidence and age patterns by year 2005 -- 2018, Eritrea (Source: Measles case-based surveillance system)

  Year   Number of suspected measles cases   Number of confirmed rubella cases   Number of confirmed measles cases   Incidence of confirmed measles per 1,000,000 population   Mean age (in years) of confirmed measles cases   Median age (in years) of confirmed measles cases   \% of measles cases unvaccinated
  ------ ----------------------------------- ----------------------------------- ----------------------------------- --------------------------------------------------------- ------------------------------------------------ -------------------------------------------------- ----------------------------------
  2005   159                                 16                                  32                                  10.6                                                      13                                               7                                                  100%
  2006   125                                 67                                  9                                   3                                                         7                                                6                                                  0%
  2007   52                                  4                                   2                                   0.6                                                       4.5                                              4.5                                                0%
  2008   61                                  1                                   1                                   0.3                                                       0                                                0                                                  0%
  2009   45                                  0                                   3                                   0.9                                                       22.3                                             25                                                 100%
  2010   168                                 47                                  6                                   1.7                                                       18.5                                             22                                                 75%
  2011   145                                 18                                  14                                  3.9                                                       18.9                                             18                                                 100%
  2012   244                                 17                                  95                                  24                                                        23.8                                             25                                                 88%
  2013   139                                 15                                  50                                  13.1                                                      23.6                                             21                                                 91%
  2014   105                                 32                                  1                                   0.3                                                       3                                                3                                                  0%
  2015   195                                 14                                  104                                 24.7                                                      25.5                                             27                                                 89%
  2016   334                                 44                                  81                                  16.8                                                      20.9                                             22                                                 81%
  2017   185                                 2                                   62                                  16.8                                                      10.7                                             9                                                  51%
  2018   155                                 5                                   69                                  17.7                                                      13.7                                             12                                                 63%

More than half (60.5%) of the confirmed measles cases reported between 2005 and 2018 are more than 15 years of age. This high proportion was also evident from 2015 - 2018, with children more than 15 years of age comprising of more than 40% of all confirmed measles cases in 2015, 2016 and 2018. Both the mean and median age of confirmed measles cases were more than 10 years in 8 of the 14 years covered by our analysis. All of the years with documented incidence of more than 1 per million (except 2006) had mean age of measles cases of more than 10 years.

Vaccination status was not documented in the records of 162 of the 529 confirmed measles cases. Of the remaining confirmed cases whose status was documented, the proportion of cases with no history of measles vaccination ranges between 51% and 89% in the years 2015 - 2018 ([Table 5](#t0005){ref-type="table"}). The comparison of the number of confirmed measles cases in the case-based surveillance database and in the official annual country report to WHO and UNICEF through the Joint Reporting Form (JRF) showed differences. In 2006, 2007 and 2015, the officially reported figure is closer to the number of suspected cases in the case-based surveillance database. However, the comparison shows significant difference in the other years. Especially in 2017, a total of 1,199 measles cases were officially reported to WHO and UNICEF, while the case based surveillance database contained 185 suspected cases of which only 65 were confirmed. There is no detailed epidemiological data or investigation report available to explain this spike in 2017 ([Table 6](#t0006){ref-type="table"}). Eritrea does not yet have any documented measles or rubella viral strains.

###### 

Comparison of the reported measles cases through the case-based surveillance system and the aggregate annual official reporting to WHO and UNICEF through the joint reporting form 2005 - 2018

  Year   Measles case reports         
  ------ ---------------------- ----- ------
  2005   159                    32    19
  2006   125                    9     128
  2007   52                     2     55
  2008   61                     1     0
  2009   45                     3     82
  2010   168                    6     51
  2011   145                    14    48
  2012   243                    95    194
  2013   139                    50    45
  2014   103                    1     127
  2015   195                    104   198
  2016   334                    81    142
  2017   185                    62    1199
  2018   155                    69    70

Discussion {#sec4}
==========

Eritrea has made significant progress towards measles elimination. The country has managed to sustain very high coverage with MCV1 for more than 10 years and an equally high coverage with the second dose of measles vaccine since it started reporting MCV2 coverage. The dropout rate between these two doses is less than 11% at national level in the three years of reporting. However, coverage is not homogeneous across all Zobas especially for MCV2 coverage. In order to achieve and sustain measles elimination, Eritrea will need to reach at least 95% coverage with both MCV1 and MCV2.

The fact that Eritrea has had low routine immunization and SIAs administrative coverage, but significantly high coverage by surveys indicates that the official population figures may be overestimated. These denominator figures are generated as projections. Eritrea has never done any census. The wide age-range MR SIAs of 2018 has attained ≥ 95% coverage by survey across all provinces, and it will likely take care of any immunity gaps among the targeted population of children 9 months to 15 years of age. The expected impact of the MR SIAs on measles and rubella incidence among the targeted cohort of children under 15 years of age will need to be documented through a sensitive surveillance system \[[@cit0014]\].

The total number of measles cases reported has markedly declined following the SIAs in 2003. Incidence of confirmed measles has been low until 2012. In the years 2013 - 2018, measles incidence rate was between 10 and 20 per million population despite the high coverage attained for many years. The country has had a large proportion of school age children and adults among measles cases in the past decade, with mean age of confirmed measles being higher than 10 years of age. It is evident that measles incidence is driven by susceptible in the adolescent and adult age group. This epidemiological shift to older age groups can be explained on the low population density and the relatively high measles vaccination coverage over the last two decades \[[@cit0015]\].

Measles surveillance is integrated with active surveillance for acute flaccid paralysis in Eritrea. However, there are gaps in case-based surveillance performance for measles, with the country failing to attain the target for district reporting since 2011. Information on the vaccination status of cases was missing in 30% of the 529 confirmed cases from 2005 - 2018. These performance gaps will need to be addressed through further investigation to identify the specific non-reporting districts and the factors leading to the weak performance. In addition, there is a need to investigate and document all outbreaks of measles in order to identify the specific populations that may be at risk and take the necessary measures. This will help to better understand the epidemiological factors and populations at risk in Eritrea.

With the gaps documented in surveillance performance, the information on incidence from the surveillance system will need to be interpreted cautiously. The analysis has shown that the surveillance system was not able to launch a detailed investigation and documentation on the febrile rash illness cases which occurred in 2017 as reported to WHO through the joint reporting format. In addition, the discrepancy in the number of measles cases reported in various years through the case-based surveillance system and the annual summary reports to WHO and UNICEF indicates the need for regular harmonization of data, and for aggressive efforts to investigate all suspected cases and take timely programmatic action to limit measles outbreaks spread as much as possible.

The national EPI policy emphasizes that immunization service provision will be done as an integral part of the primary health care services including prevention and control of childhood diseases, growth monitoring, information, education and communication, nutritional advice, ante-natal, post-natal care and family planning. It also states that provision of insecticide treated bednets, vitamin A supplementation and de-worming shall be supplied through routine immunization and campaign settings, with a view to reduce missed opportunities. Eritrea is eligible for Global Alliance for Vaccines and Immunization (GAVI) support. Starting from 2016 the government has started co-financing 20% of the total costs on traditional vaccines, including measles vaccine \[[@cit0004]\].

The sustained high immunization coverage in Eritrea is a function of the strength of the immunization program. A national immunization program review done in 2016 identified programmatic strengths that included the delivery of integrated services offered 6 days a week, very good caretaker awareness of the benefits of immunization and high demand for services. However, it was also noted that lack of transportation may pose a risk of delaying vaccine availability to the population, and to reaching out to hard to reach populations \[[@cit0016], [@cit0017]\]. The country has conducted very good programmatic preparation and roll out of MCV2 which has also contributed very well to the sustained high coverage of MCV2 \[[@cit0017], [@cit0018]\]. Following the introduction of MCV2, an evaluation done in April 2015 found out that staff knowledge was satisfactory, monitoring of service data was being done systematically, cold chain capacity was adequate, supervisory support to the health facility level was being provided regularly and that the community awareness of the vaccine schedule was good. However, the evaluation identified the need for more active monitoring of adverse events following immunisation \[[@cit0018]\].

It has been documented that having a cadre of community health workers, immunization services tailored to community needs, health system and community partnership, and a regular review of health worker performance are key drivers of improvement in district level immunization program coverage in the African context \[[@cit0019]\]. The HSSDP II plans to expand and improve the work of community health workers guided by an integrated comprehensive community strategy. In the area of maternal and child health, there are plans to scale up community involvement on microplanning at district level to address population groups in less accessible geographical areas \[[@cit0003]\]. These activities will have a strong impact on the progress towards sustainable measles elimination in Eritrea.

The World Health Organisation has developed a framework for the verification of measles elimination which has set the criteria for defining measles elimination and the processes for verifying measles elimination in a country. The framework requires that countries establish the necessary independent structures responsible for compiling the programmatic and epidemiological information necessary to assess progress and document, measles elimination \[[@cit0020]\]. This includes the establishment of National Verification Committees (NVC) with the primary responsibility for guiding countries in the preparation of their documentation of progress towards the achieve¬ment of measles elimination and the Regional Verification Commission (RVC), which validates and verifies elimination in each country and eventually in the Region \[[@cit0021]\]. As of April 2019, Eritrea has not yet established an NVC or started the documentation of progress towards measles elimination.

**Limitations:** this study has limitations. First, there may be inaccuracies in administrative coverage monitoring. Surveys have been shown to provide higher coverage than reported data due to inaccuracies of denominators used for coverage monitoring. Secondly, the study did not look at the measles laboratory performance indicators or the quality of serological specimens. Thirdly, the weaknesses in surveillance performance and the gaps in the investigation of cases and outbreaks may conceal the true incidence and epidemiological pattern of measles in the country.

Conclusion {#sec5}
==========

In order to further advance towards the measles elimination goal, we recommend that Eritrea strengthen its surveillance system, investigate and fully document outbreaks of measles, ensure that all districts report and investigate suspected cases, conduct regular risk assessment to identify and address immunity gaps. The triangulation of data from coverage monitoring, surveillance and risk assessment exercises helps to target tailored interventions within the routine immunization service delivery platform or through the Periodic Intensification of Routine Immunization (PIRI) model \[[@cit0022]\]. With the current levels of coverage in the childhood population, the country can extend its inter-SIAs interval to 4 - 5 years, without risking a rapid accumulation of young children susceptible to measles infection. Depending on the findings from risk assessment exercises and disease surveillance, SIAs may be tailored to target susceptible adolescent and adult populations in specific areas, in addition to young cohorts. Eritrea should set up a national verification committee to document the progress with measles elimination. This will serve as an opportunity to raise the profile of measles elimination in the national health agenda, and to advocate for rubella/congenital rubella syndrome (CRS) control in the country. As a way of monitoring the impact of the introduction of rubella vaccine, the country should consider doing a retrospective review of CRS in a few tertiary care centers and initiate sentinel CRS surveillance on a prospective basis.

What is known about this topic {#sec5.1}
------------------------------

-   Eritrea has managed to reduce under five and infant mortality significantly in the past 25 years;

-   Eritrea has been implementing measles elimination strategies since 2003;

-   Eritrea introduced measles vaccine MCV2 in 2012.

What this study adds {#sec5.2}
--------------------

-   Eritrea has maintained high MCV1 and MCV2 coverage, with drop-out rates of less than 11% between the two doses;

-   Measles surveillance performance gaps persist, and there is a discrepancy in the number of reported measles cases between the case-based surveillance data and aggregate reporting;

-   The mean and median age of measles cases in Eritrea has been mostly above 10 years in the past 15 years.
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